アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley with subfirm xiromed - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 80 mg

アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley with subfirm xiromed - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 20 mg

アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley with subfirm xiromed - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 10 mg

アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley with subfirm xiromed - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 40 mg

アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 20 mg

アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 10 mg

アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 5 mg

アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 40 mg

欧州連合 - アイスランド語 - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - sykursýki, tegund 2 - lyf notuð við sykursýki - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

欧州連合 - アイスランド語 - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - sykursýki, tegund 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 fyrir tiltæk gögn um mismunandi samsetningar).